KX2-391 Dihydrochloride: Dual Src Kinase and Tubulin Inhibitor in Cancer and HBV Research

Executive Summary: KX2-391 dihydrochloride (also known as Tirbanibulin dihydrochloride or KX-01 dihydrochloride) is a dual mechanism small molecule inhibitor that targets both Src kinase and tubulin polymerization at nanomolar concentrations (IC50 = 23–39 nM for Src; ≥80 nM for tubulin) (Chen et al., 2023). The compound blocks HBV transcription by suppressing the precore promoter (EC50 = 0.14–2.7 μM in cell models) and inhibits botulinum neurotoxin A (BoNT/A) activity at micromolar levels. KX2-391 dihydrochloride is supplied by APExBIO and is clinically validated for topical treatment of actinic keratosis and oral dosing in oncology. Its mechanism and translational relevance are supported by robust, peer-reviewed evidence, making it a critical tool for dissecting Src, tubulin, and HBV signaling pathways.
Key facts and workflow guidance are detailed below with inline, stable citations.

Biological Rationale

Src kinase is a non-receptor tyrosine kinase implicated in oncogenic signaling, metastatic progression, and cytoskeletal remodeling (Chen et al., 2023). Elevated Src expression correlates with poor prognosis and metastasis in colorectal cancer (CRC), as shown by quantitative RT-PCR and immunohistochemistry. Tubulin polymerization is essential for mitotic spindle assembly and cell division. Disruption of the tubulin cytoskeleton halts mitosis, leading to cell cycle arrest and apoptosis. HBV infection and replication depend on specific promoter activity and host signaling. BoNT/A exerts neurotoxic effects by cleaving SNAP-25, disrupting neurotransmitter release. Dual inhibition of Src kinase and tubulin polymerization simultaneously impairs cell proliferation, migration, and viral replication, providing a multi-pronged approach to disease intervention. KX2-391 dihydrochloride addresses these biological axes by direct molecular targeting, validated in both preclinical and clinical settings.

Mechanism of Action of KX2-391 dihydrochloride

KX2-391 dihydrochloride exerts its effects via two principal mechanisms:

• Src kinase inhibition: The compound binds the substrate-binding site of the Src kinase domain, blocking downstream phosphorylation events involved in cell proliferation and metastasis. Reported cellular IC50 values are 23 nM (NIH3T3/c-Src527F) and 39 nM (SYF/c-Src527F).
• Tubulin polymerization inhibition: KX2-391 dihydrochloride interacts with a novel site on the α-β tubulin heterodimer, distinct from colchicine or vinca alkaloid sites. Inhibition is observed at concentrations ≥80 nM, resulting in mitotic arrest and cytoskeletal disruption.
• Anti-HBV activity: The compound suppresses hepatitis B virus transcription by targeting the HBV precore promoter, with EC50 values of 0.14 μM in PXB cells and 2.7 μM in HepG2-NTCP cells.
• BoNT/A inhibition: KX2-391 dihydrochloride inhibits SNAP-25 cleavage mediated by BoNT/A light chain at 10–40 μM concentrations, interfering with neurotoxin-induced paralysis.

This dual mechanism enables pathway-selective intervention in cancer, viral, and neurotoxin pathobiology (Chen et al., 2023).

Evidence & Benchmarks

• KX2-391 dihydrochloride inhibits Src kinase in cellular models at IC50 values of 23 nM (NIH3T3/c-Src527F) and 39 nM (SYF/c-Src527F) (Chen et al., 2023).
• Inhibition of tubulin polymerization is observed at concentrations ≥80 nM in purified tubulin assays and cell-based models (Chen et al., 2023).
• Anti-HBV activity is demonstrated with EC50 values of 0.14 μM in PXB cells and 2.7 μM in HepG2-NTCP cells; plasma concentrations ≥560 nM are required for in vivo efficacy (Chen et al., 2023).
• BoNT/A neurotoxin activity is inhibited at 10–40 μM, blocking SNAP-25 cleavage in neuronal assays (Chen et al., 2023).
• Oral administration in mice at 5–15 mg/kg (once or twice daily) and in chimpanzees at 1 mg/kg twice daily achieves anti-HBV effects (Chen et al., 2023).
• The compound is clinically validated for topical use (1% ointment; 10 mg/g) in actinic keratosis and oral dosing (40–120 mg/day) in oncology (Chen et al., 2023).

For a detailed mechanistic extension, see "KX2-391 Dihydrochloride: Unraveling Pathway-Specific Modulation", which focuses on pathway dissection, whereas this article provides bench-to-clinic benchmarks.

Applications, Limits & Misconceptions

KX2-391 dihydrochloride is widely used in:

• Cancer research: As a dual Src kinase and tubulin polymerization inhibitor, it is used to study cell migration, invasion, and mitosis in vitro and in vivo.
• Anti-HBV research: The compound suppresses HBV transcription and replication, with validated efficacy in preclinical models.
• Neurotoxin inhibition: It is applied in BoNT/A activity assays to prevent SNAP-25 cleavage.
• Clinical applications: Approved for actinic keratosis (topical 1% ointment) and evaluated in oncology trials (oral 40–120 mg/day).

For translational and workflow insights, refer to "KX2-391 Dihydrochloride: Redefining Translational Research", which provides deployment strategies, while this article delivers concrete parameterization for experimental design.

Common Pitfalls or Misconceptions

• KX2-391 dihydrochloride is not a pan-kinase inhibitor; its primary kinase target is Src, with minimal off-target effects at recommended doses.
• It is insoluble in water; DMSO (≥25.2 mg/mL) or ethanol (≥48.8 mg/mL, gentle warming) are required for stock solutions.
• The compound does not inhibit viral entry; its anti-HBV effect is via transcriptional suppression.
• Peripheral neuropathy is not a significant risk at clinical doses, unlike other tubulin inhibitors.
• BoNT/A inhibition requires higher (10–40 μM) concentrations than those used for anticancer or anti-HBV activity.

For a comprehensive review of limitations, see "KX2-391 Dihydrochloride: Dual Mechanism Src & Tubulin Inhibitor", which additionally covers comparative agent selectivity.

Workflow Integration & Parameters

Preparation and Storage: KX2-391 dihydrochloride (A3535) is supplied as a solid by APExBIO. Stock solutions are prepared in DMSO or ethanol. Store at -20°C, protected from light and moisture.

• In vitro concentrations: 0.013–10 μM for cancer and HBV studies; 10–40 μM for BoNT/A assays.
• In vivo dosing: Mice: 5–15 mg/kg (oral, once or twice daily); Chimpanzees: 1 mg/kg (oral, twice daily).
• Clinical: Topical: 1% ointment (10 mg/g); Oral: 40–120 mg/day (oncology).
• Solubility: DMSO ≥25.2 mg/mL; Ethanol ≥48.8 mg/mL with gentle warming; insoluble in water.

For workflow troubleshooting and advanced applications, see "KX2-391 Dihydrochloride: Dual Src and Tubulin Inhibitor for Advanced Applications", which elaborates on troubleshooting and advanced parameters not covered here.

Conclusion & Outlook

KX2-391 dihydrochloride (Tirbanibulin dihydrochloride) is a validated, dual mechanism inhibitor with nanomolar potency against Src kinase and tubulin polymerization. Its unique substrate-binding selectivity, clinical tolerability, and broad utility in cancer, HBV, and neurotoxin research are supported by robust peer-reviewed data and product benchmarks. The compound, available from APExBIO, enables precise interrogation and modulation of key signaling pathways, with established protocols for in vitro, in vivo, and clinical use. Future directions include expanded use in combination therapies and mechanistic dissection of tubulin and kinase signaling in disease models. For product details and ordering, refer to the KX2-391 dihydrochloride product page.